Sanofi (SNY.US) Q3 profit surpasses expectations; strong Dupixent demand cannot mask patent cliff concerns

According to information from Zhihui CAIJING APP, driven by growing demand for its best-selling skin and asthma drug Dupixent (dupilumab), Sanofi has raised its full-year sales and profit forecasts for the second consecutive quarter. The French pharmaceutical company stated on Friday that, at constant exchange rates, its sales this year are expected to achieve low double-digit percentage growth, higher than the previously forecast 10%. Earnings per share, excluding certain items, are expected to achieve mid double-digit percentage growth.